Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
34.6M
-
Shares change
-
-108K
-
Total reported value, excl. options
-
$55.4M
-
Value change
-
-$51.5K
-
Put/Call ratio
-
1.9
-
Number of buys
-
32
-
Number of sells
-
-30
-
Price
-
$1.60
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q4 2022
91 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q4 2022.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.6M shares
of 166M outstanding shares and own 20.9% of the company stock.
Largest 10 shareholders include BVF INC/IL (6.6M shares), VANGUARD GROUP INC (4.59M shares), TANG CAPITAL MANAGEMENT LLC (3.51M shares), ACADIAN ASSET MANAGEMENT LLC (2.65M shares), Rubric Capital Management LP (2.41M shares), MILLENNIUM MANAGEMENT LLC (1.72M shares), RENAISSANCE TECHNOLOGIES LLC (1.34M shares), Laurion Capital Management LP (1.27M shares), Assenagon Asset Management S.A. (915K shares), and TWO SIGMA INVESTMENTS, LP (741K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.